(Q47244891)

English

The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients

scientific article published on 27 December 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

2 references

Europe PubMed Central

23 December 2020

The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients (English)

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

1 reference

23 December 2020

synovial sarcoma

1 reference

based on heuristic

inferred from title

author name string

Seth M Pollack

1

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

publication date

27 December 2017

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

1 February 2018

1 reference

23 December 2020

Expert Review of Vaccines

2 references

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

23 December 2020

17

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

2

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

107-114

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

copyright license

Creative Commons Attribution-NonCommercial-NoDerivatives

1 reference

23 December 2020

Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11)

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Liposarcoma: molecular genetics and therapeutics.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Taking dendritic cells into medicine

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Designing vaccines based on biology of human dendritic cell subsets

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

On the Role of Dendritic Cells Versus Other Cells in Inducing Protective CD8+ T Cell Responses

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

DC-SIGN and L-SIGN Can Act as Attachment Receptors for Alphaviruses and Distinguish between Mosquito Cell- and Mammalian Cell-Derived Viruses

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Engineered lentivector targeting of dendritic cells for in vivo immunization

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Heterologous prime-boost vaccination.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Lentiviral vector followed by protein immunisation breaks tolerance against the self-antigen Her1 and results in lung cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Cancer/testis antigens, gametogenesis and cancer

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Imaging the cranial nerves in cancer

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2018.1419068

21 January 2018

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lentivirally transduced dendritic cells as a tool for cancer immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cancer/testis genes: review, standardization, and commentary.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myxoid\round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29280411

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/14760584.2018.1419068

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6521962

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47244891&oldid=2147749162"